Biosenic (LTS:0R55) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is Biosenic Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Biosenic's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0R55 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Biosenic's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosenic Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosenic's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Biosenic's Margin of Safety % (DCF Earnings Based) falls into.


Biosenic Business Description

Address Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.